{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:14:18Z","timestamp":1791080058292,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.cyto.2013.04.016","type":"journal-article","created":{"date-parts":[[2013,5,7]],"date-time":"2013-05-07T19:58:46Z","timestamp":1367956726000},"page":"105-112","source":"Crossref","is-referenced-by-count":25,"title":["CXCL10 antagonism and plasma sDPPIV correlate with increasing liver disease in chronic HCV genotype 4 infected patients"],"prefix":"10.1016","volume":"63","author":[{"given":"Dina","family":"Ragab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Laird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darragh","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armanda","family":"Casrouge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"Mamdouh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Abass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina El.","family":"Shenawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelhadi M.","family":"Shebl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wagdi F.","family":"Elkashef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled R.","family":"Zalata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamal","family":"Esmat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Bonnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Fontanet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Rafik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L.","family":"Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2013.04.016_b0005","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1469-0691.2010.03432.x","article-title":"Evolving epidemiology of hepatitis C virus","volume":"17","author":"Lavanchy","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cyto.2013.04.016_b0010","doi-asserted-by":"crossref","first-page":"14757","DOI":"10.1073\/pnas.1008877107","article-title":"Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt","volume":"107","author":"Miller","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cyto.2013.04.016_b0015","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(99)06527-7","article-title":"The role of parenteral antichistosomal therapy in the spread of hepatitis C virus in Egypt","volume":"355","author":"Frank","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.cyto.2013.04.016_b0020","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1189\/jlb.0303093","article-title":"Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation","volume":"74","author":"Harvey","year":"2003","journal-title":"J Leukocyte Biol"},{"key":"10.1016\/j.cyto.2013.04.016_b0025","doi-asserted-by":"crossref","first-page":"7149","DOI":"10.3748\/wjg.14.7149","article-title":"Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection","volume":"14","author":"Larrubia","year":"2008","journal-title":"World J Gastoenterol"},{"key":"10.1016\/j.cyto.2013.04.016_b0030","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood-2005-01-0126","article-title":"Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C","volume":"106","author":"Butera","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2013.04.016_b0035","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/gut.2005.074062","article-title":"Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C","volume":"55","author":"Diago","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.cyto.2013.04.016_b0040","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1002\/hep.21407","article-title":"IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection","volume":"44","author":"Lagging","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.cyto.2013.04.016_b0045","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1177\/135965350801300815","article-title":"IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection","volume":"13","author":"Reiberger","year":"2008","journal-title":"Antiviral Ther"},{"key":"10.1016\/j.cyto.2013.04.016_b0050","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1086\/507307","article-title":"Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection","volume":"194","author":"Romero","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cyto.2013.04.016_b0055","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1172\/JCI40594","article-title":"Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV","volume":"121","author":"Casrouge","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cyto.2013.04.016_b0060","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-2249.2011.04488.x","article-title":"Discrimination of agonist and antagonist forms of CXCL10 in biological samples","volume":"167","author":"Casrouge","year":"2012","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.cyto.2013.04.016_b0065","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/hep.1840200104","article-title":"Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C","volume":"20","author":"Bedossa","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.cyto.2013.04.016_b0070","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/hep.22500","article-title":"Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C","volume":"48","author":"Zeremski","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cyto.2013.04.016_b0075","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1172\/JCI40594","article-title":"Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV","volume":"121","author":"Casrouge","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cyto.2013.04.016_b0080","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1365-3083.1991.tb02548.x","article-title":"Expression of CD26 (dipeptidyl peptidase IV) on resting and activated human T-lymphocytes","volume":"33","author":"Mattern","year":"1991","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.cyto.2013.04.016_b0085","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.biocel.2007.12.009","article-title":"Proteolytic processing of chemokines: implications in physiological and pathological conditions","volume":"40","author":"Wolf","year":"2008","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.cyto.2013.04.016_b0090","doi-asserted-by":"crossref","first-page":"29839","DOI":"10.1074\/jbc.M103106200","article-title":"Kinetic investigation of chemokine truncation by CD26\/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family","volume":"276","author":"Lambeir","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cyto.2013.04.016_b0095","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1189\/jlb.72.1.183","article-title":"Dipeptidyl peptidase IV (CD26) on T cells cleaves the CXC chemokine CXCL11 (I-TAC) and abolishes the stimulating but not the desensitizing potential of the chemokine","volume":"72","author":"Ludwig","year":"2002","journal-title":"J Leukocyte Biol"},{"key":"10.1016\/j.cyto.2013.04.016_b0100","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1592\/phco.30.5.463","article-title":"Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus","volume":"30","author":"Neumiller","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cyto.2013.04.016_b0105","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jhep.2006.07.011","article-title":"Insulin resistance and HCV: will new knowledge modify clinical management?","volume":"45","author":"Negro","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.cyto.2013.04.016_b0110","doi-asserted-by":"crossref","first-page":"7075","DOI":"10.3748\/wjg.v12.i44.7075","article-title":"Insulin resistance and hepatitis C","volume":"12","author":"Romero-Gomez","year":"2006","journal-title":"World J Gastroenterol"}],"updated-by":[{"DOI":"10.1016\/j.cyto.2013.09.013","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000}}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466613001816?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466613001816?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T15:06:26Z","timestamp":1688223986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466613001816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S1043466613001816"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2013.04.016","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.cyto.2013.09.013","asserted-by":"object"}]},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}